There are currently sound scientific data to support the use a non-pharmacological approach for the management of patients with irritable bowel syndrome (IBS). The nutritionally based low of Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols (FODMAPs) diet is gaining acceptance globally among clinicians and patients alike. Despite the high success rate reported by some institutions, many more report a high treatment failure rate. This disparity has been blamed in many cases on the difficulty to implement the diet, leading to poor compliance and the poor results. Although some solutions such as dietician support, and portable phone applications have been developed to address these challenges, the lack of clear labeling of the FODMAP content and its beneficial effects in most processed foods remain a major issue. Identification of the FODMAP content in such foods may not be accurate due to the presence of unlabeled substrates or alteration in FODMAP content arising from the processing of the food product. Systemic FODMAP content analyses on such products are therefore necessary using standardized methods. Current food regulations limit the ability for food companies to develop products with the appropriate labels for people with IBS symptoms. The FODMAP labeling that is currently used in certain countries such as Australia can be more problematic in other geographies such as Europe or Brazil. CONCLUSION: While the evidence to support the use of a low FODMAP diet is strong, the ability for consumers to properly identify foods which are suitable for this diet is problematic. Clinicians, patients, food manufacturers and food regulators should work collaboratively to develop solutions to modify the regulatory landscape, and increase the availability and access to safer and lower cost solutions for this population with a high unmet need.